Abstract
Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
MeSH terms
-
Adolescent
-
Anti-Bacterial Agents / administration & dosage*
-
Anti-Bacterial Agents / standards
-
Antibiotic Prophylaxis / standards*
-
Antibiotic Prophylaxis / statistics & numerical data*
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / therapeutic use
-
Child
-
Child, Preschool
-
Humans
-
Immunocompromised Host
-
Neoplasms / drug therapy*
-
Pneumonia, Pneumocystis / microbiology
-
Pneumonia, Pneumocystis / prevention & control*
-
Retrospective Studies
-
Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*
-
Trimethoprim, Sulfamethoxazole Drug Combination / standards
Substances
-
Anti-Bacterial Agents
-
Antineoplastic Agents
-
Trimethoprim, Sulfamethoxazole Drug Combination